EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Outcomes of aortic stenosis in patients with cardiac amyloidosis: A systematic review and meta-analysis

Soban Ahmad, Muhammad Junaid Ahsan, Morgan Newlun, Mitchell Sand, Anan Abu Rmilah, Amman Yousaf, Muhammad Asim Shabbir, Shahbaz A Malik, Andrew M Goldsweig

Cardiovascular Revascularization Medicine · 2025-04 · 73 · 98-106

DOI: 10.1016/j.carrev.2025.02.005 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cardiovascular Revascularization Medicine, 2025-04. Verfasst von Soban Ahmad und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: soahmad@unmc.edu. Hauptthemen laut MEDLINE: Amyloidosis, Aortic Valve, Aortic Valve Stenosis, Cardiomyopathies. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cardiac amyloidosis (CA) results from the deposition of abnormally folded protein fibrils, leading to restrictive cardiomyopathy, valvular heart disease, and arrhythmias. Up to 15 % of patients with severe aortic stenosis (AS) have concomitant CA (AS-CA). We conducted this systematic review and meta-analysis to compare medical management, transcatheter aortic valve replacement (TAVR), and surgical AVR (SAVR) in AS-CA. METHODS: A comprehensive literature search was conducted for relevant studies from inception through January 20, 2024. Studies exploring outcomes in adult AS patients with and without CA receiving medical therapy, TAVR, or SAVR were included in this analysis. RESULTS: Fifteen studies including 253,334 patients (AS-CA 6704; AS alone 246,630) were identified. AS-CA patients had significantly higher all-cause mortality (RR = 2.60, 95 % CI 1.48-4.57, P = 0.0009) compared to AS alone. Among patients with AS-CA, TAVR was associated with lower all-cause mortality compared to both medical therapy (RR = 0.50, 95 % CI 0.29-0.89, P = 0.02) and SAVR (RR = 0.41, 95 % CI 0.22-0.78, P = 0.007). AS-CA patients undergoing TAVR were more likely to have paradoxical low-flow, low-gradient AS (RR = 1.56, 95 % CI 1.15-2.12, P = 0.04) at baseline and had a higher risk of post-TAVR acute kidney injury (RR = 1.95, 95 % CI 1.35-2.80, P = 0.0003) compared to patients undergoing TAVR for AS alone. There were similar risks of other post-TAVR complications, including major bleeding, vascular complications, stroke, and new pacemaker implantation between AS-CA and AS alone. CONCLUSION: CA is associated with a higher mortality in patients with severe AS. In patients with concomitant AS and CA, TAVR is safe and associated with better survival than medical therapy or SAVR. SOCIAL MEDIA ABSTRACT: #Meta-Analysis: Cardiac amyloidosis is associated with increased mortality in severe AS. #TAVR is safe in amyloidosis & improves survival more than medical therapy or SAVR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmyloidosisAortic ValveAortic Valve StenosisCardiomyopathiesCardiovascular AgentsHeart Valve Prosthesis ImplantationTranscatheter Aortic Valve ReplacementHumansRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTreatment Outcome

Stichwörter der Autor:innen

Aortic stenosis (AS)Cardiac amyloidosis (CA)Meta-analysisMortalitySurgical aortic valve replacement (SAVR)Transcatheter aortic valve replacement (TAVR)

Substanzen

Cardiovascular Agents

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: soahmad@unmc.edu.
  • Department of Cardiovascular Medicine, Baylor University Medical Center, Dallas, TX, USA.
  • Department of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
  • Department of Medicine, Magnolia Regional Health Center, Corinth, MS, USA.
  • Department of Medicine, McLaren Flint-Michigan State University, Flint, MI, USA.
  • Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

Zitieren

APA

Ahmad, S., Ahsan, M. J., Newlun, M., Sand, M., Rmilah, A. A., Yousaf, A., Shabbir, M. A., Malik, S. A., & Goldsweig, A. M. (2025). Outcomes of aortic stenosis in patients with cardiac amyloidosis: A systematic review and meta-analysis. Cardiovascular Revascularization Medicine, 73, 98-106. https://doi.org/10.1016/j.carrev.2025.02.005

Vancouver

Ahmad S, Ahsan MJ, Newlun M, Sand M, Rmilah AA, Yousaf A, et al. Outcomes of aortic stenosis in patients with cardiac amyloidosis: A systematic review and meta-analysis. Cardiovascular Revascularization Medicine. 2025;73:98-106. doi:10.1016/j.carrev.2025.02.005

BibTeX
@article{Ahmad2025,
  author = {Ahmad, Soban and Ahsan, Muhammad Junaid and Newlun, Morgan and Sand, Mitchell and Rmilah, Anan Abu and Yousaf, Amman and Shabbir, Muhammad Asim and Malik, Shahbaz A and Goldsweig, Andrew M},
  title = {Outcomes of aortic stenosis in patients with cardiac amyloidosis: A systematic review and meta-analysis},
  journal = {Cardiovascular Revascularization Medicine},
  year = {2025},
  volume = {73},
  pages = {98--106},
  doi = {10.1016/j.carrev.2025.02.005}
}
Kostenlos starten →